Loading the security page…
A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
Repligen makes the filters and columns used to purify biologic drugs during manufacturing.
A biologic drug is produced by living cells, and the resulting liquid must be separated, concentrated and purified. The company makes the consumables for those steps — membranes, columns, sensors. They are written into the manufacturing procedure and into the drug's registration dossier, so replacing one requires regulatory approval.
Hence a supplier position locked in for the medicine's whole life, and revenue that grows with production volume rather than with equipment sales. The industry lived through a severe downturn: customers stockpiled during the pandemic and stopped ordering for years. Risks: the inventory cycle, biotech funding and demand in China. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Repligen Corporation (RGEN) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Repligen Corporation (RGEN) on November 3, 2026 is 179.86 $, +4.00 % on the day. Over 52 weeks the stock traded between 100.99 $ and 198.87 $; the price now sits 81 % of the way up that range. Over the past year the price changed by +23.17 %. The P/E ratio is 237.98, which is above the sector median (24.61). Market capitalization is 9.89 billion $, rank 11 among 132 stocks of the same industry with a known capitalization.
Repligen Corporation trades on Nasdaq under the ticker RGEN. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks RGEN has traded between 100.99 $ and 198.87 $. As of 3 November 2026 the price stood 84.98 % of the way from the 52-week low to the high.
Over one year RGEN shares rose 23.17 %; over six months they rose 44.91 %. Volatility over 90 days is 50.04 %. Dividends are not included: this is price change only, as of 3 November 2026.
RGEN trades at a price-to-earnings ratio of 238, above the sector median of 24.6. Price to sales is 12.6, above the sector median of 3.6. Price to book is 4.7, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Repligen Corporation reported revenue of 785M $ and net income of 42M $ over the last four quarters. Net margin is 5.29 %. Revenue changed by +16.49 % year over year. Earnings per share are 0.73 $. Market capitalisation is 9.9B $.
RGEN has a return on equity of 1.97 %, above the sector median of −40.58 %. Return on assets is 1.41 %, above the sector median of −30.08 %. Operating margin is 8.23 %, above the sector median of −20.96 %.